The course of treatment for Polyethylene Glycol Losenatide Injection should be determined specifically based on the patient’s blood glucose profile and matching medication. The general usage is 0.1mg each time, subcutaneous injection in the abdomen every 7 days. Polyethylene Glycol Losenatide Injection, as a new type of insulin injection, is mainly used in conjunction with dietary control, exercise, in combination with metformin, or alone in adult type 2 diabetes mellitus patients to control blood glucose and improve the condition. When used alone, a starting dose of 0.1mg is recommended, with subcutaneous injections into the abdomen every 7 days. In addition, if glycemic control is not effective, the dose can be increased to 0.2mg every 7 days. When used in combination with metformin, a starting dose of 0.1 mg per dose is recommended for subcutaneous injection into the abdomen every 7 days. The main adverse reactions of this drug are gastrointestinal adverse reactions in the form of nausea, vomiting and diarrhea, which are mostly transient and of low incidence. It is contraindicated in patients with medullary thyroid carcinoma, family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2, and in those who have had a previous severe allergic reaction to the product or any of its components. It is recommended that this drug be used under medical supervision.